Iovance Biotherapeutics, Inc. SEC filings IOVA
Iovance Biotherapeutics, Inc. has 1,003 filings in SEC EDGAR's recent list, going back to Oct 1, 2010. Its latest annual report, Form ARS, was filed on May 1, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Apr 28, 2026 | — |
| DEF 14A | Proxy statement | Apr 28, 2026 | Jun 10, 2026 |
| PRE 14A | Preliminary proxy statement | Apr 17, 2026 | Jun 10, 2026 |
| DEFA14A | Additional proxy material | Apr 28, 2025 | — |
| DEF 14A | Proxy statement | Apr 28, 2025 | Jun 10, 2025 |
| DEFA14A | Additional proxy material | May 17, 2024 | — |
| DEFA14A | Additional proxy material | Apr 29, 2024 | — |
| DEF 14A | Proxy statement | Apr 29, 2024 | Jun 11, 2024 |
| DEFA14A | Additional proxy material | Apr 26, 2023 | — |
| DEF 14A | Proxy statement | Apr 26, 2023 | — |
| PRE 14A | Preliminary proxy statement | Apr 14, 2023 | — |
| DEFA14A | Additional proxy material | Apr 27, 2022 | — |
| DEF 14A | Proxy statement | Apr 27, 2022 | Jun 10, 2022 |
| DEFA14A | Additional proxy material | Apr 27, 2021 | — |
| DEF 14A | Proxy statement | Apr 27, 2021 | Jun 11, 2021 |
| DEFA14A | Additional proxy material | Apr 28, 2020 | — |
| DEF 14A | Proxy statement | Apr 27, 2020 | Jun 8, 2020 |
| DEFA14A | Additional proxy material | May 1, 2019 | — |
| DEF 14A | Proxy statement | Apr 29, 2019 | Jun 10, 2019 |
| PRE 14A | Preliminary proxy statement | Apr 19, 2019 | Apr 19, 2019 |
| DEFA14A | Additional proxy material | Apr 27, 2018 | — |
| DEF 14A | Proxy statement | Apr 25, 2018 | Jun 6, 2018 |
| DEFA14A | Additional proxy material | Apr 20, 2017 | — |
| DEF 14A | Proxy statement | Apr 20, 2017 | Jun 1, 2017 |
| PRE 14A | Preliminary proxy statement | Apr 6, 2017 | Apr 6, 2017 |
| DEFA14A | Additional proxy material | Jul 26, 2016 | — |
| DEF 14A | Proxy statement | Jul 7, 2016 | Aug 16, 2016 |
| PRE 14A | Preliminary proxy statement | Jun 17, 2016 | Jun 17, 2016 |
| DEFA14A | Additional proxy material | Apr 28, 2016 | — |
| DEF 14A | Proxy statement | Apr 28, 2016 | Jun 10, 2016 |
| DEF 14A | Proxy statement | Apr 30, 2015 | Jun 12, 2015 |
| DEFA14A | Additional proxy material | Sep 23, 2014 | — |
| DEF 14A | Proxy statement | Sep 23, 2014 | Nov 3, 2014 |
| DEF 14C | Information statement | Aug 20, 2013 | Aug 22, 2013 |
| PRE 14C | Preliminary information statement | Aug 9, 2013 | Aug 15, 2013 |
Showing 35 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- IOVA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Carlos, CA
- SEC filer status
- Accelerated filer
- SEC CIK
- 1425205
- Former names
- Lion Biotechnologies, Inc. (until Jun 5, 2017); Genesis Biopharma, Inc (until Sep 23, 2013); FREIGHT MANAGEMENT CORP (until Mar 8, 2010)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.